[Form 4] AnaptysBio, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing for AnaptysBio, Inc. (ANAB) dated 07/03/2025 discloses that director Hollings Renton executed expiring stock options and immediately sold most of the resulting shares under a pre-arranged Rule 10b5-1 trading plan.

• Option exercise: 20,925 options were exercised at an exercise price of $6.93 (grant dated 07/06/2015, expiring 07/05/2025).
• Share sales: • 7,250 shares sold at a weighted-average $23.0908 • 13,675 shares sold at a weighted-average $23.8232. The weighted-average sale ranges were $22.425–$23.395 and $23.56–$24.015, respectively.
• Post-transaction holdings: Direct common-stock ownership declined from 25,890 to 4,965 shares. The insider retains ≥112,051 additional option shares that vest per their original schedules.
• The trades were executed pursuant to a Rule 10b5-1 plan adopted on 03/14/2024, signalling pre-planned, non-discretionary activity ahead of the 07/05/2025 option expiration.

The filing represents routine expiration-driven option exercise coupled with partial monetisation. While the insider’s direct share count fell by roughly 81%, his large remaining option position maintains exposure to future upside. No company operational or financial metrics are included; the disclosure is limited to insider ownership changes.

Positive

• Director retains economic exposure through at least 112,051 unexercised option shares, indicating continued alignment with shareholder interests.

Negative

• Direct common-stock holdings decreased by approximately 81% (from 25,890 to 4,965 shares), which some investors may interpret as reduced insider confidence.

Insights

Securities Analyst

TL;DR Routine option exercise; director sells ~81% of new shares, retains large option pool—mildly negative signalling but limited overall impact.

The transaction appears largely mechanical: options granted in 2015 were within days of expiry, obligating exercise or forfeiture. Mr. Renton exercised 20,925 shares at $6.93 and liquidated 20,925 – 4,965 = 15,960 shares at ~$23, crystallising an immediate spread of roughly $16 per share (≈$0.34 M before taxes). Direct ownership shrank, which can be perceived as a modestly bearish signal, yet the sale was governed by a 10b5-1 plan. Importantly, the insider still holds over 112 K option shares, preserving economic alignment with shareholders. Given ANAB’s average daily volume and the small absolute share count, I categorise the market impact as not impactful and assign a rating of 0 (neutral).

Corporate Governance Expert

TL;DR Pre-planned 10b5-1 trades reduce optics of insider selling risk; governance compliance looks sound.

The filing follows good governance practice: (1) use of a 10b5-1 plan, adopted well before execution, (2) full price-range disclosure, and (3) clear footnotes on remaining awards. From a governance perspective, the exercise-and-sell sequence prevents option expiration while avoiding open-window timing concerns. Although the insider’s direct stake is smaller, his unvested/vested options keep him properly incentivised. I deem the event non-material for governance risk and assign a neutral impact rating.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RENTON HOLLINGS

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2025		M		20,925	A	$6.93	25,890	D
Common Stock	07/02/2025		S(1)		7,250	D	$23.0908(2)	18,640	D
Common Stock	07/02/2025		S(1)		13,675	D	$23.8232(3)	4,965	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock	$6.93	07/02/2025		M			20,925	(4)	07/05/2025	Common Stock	20,925	$0	0(5)	D

Explanation of Responses:

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options, including the options exercised and sold under this Form 4, which have an expiration date of July 5, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.425 to $23.395 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.56 to $24.015 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The stock option grant was issued on July 6, 2015, is fully vested and exercisable until its expiration date of July 5, 2025.

5. In addition to the remaining options to purchase 20,925 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 112,051 shares of common stock, which options vest according to their terms.

	/s/ Eric Loumeau, Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many AnaptysBio (ANAB) shares did the director sell?

Hollings Renton sold 7,250 shares at ~$23.09 and 13,675 shares at ~$23.82, totalling 20,925 shares on 07/02/2025.

What was the exercise price of the options in AnaptysBio's Form 4?

The options were exercised at an exercise price of $6.93 per share.

Does the insider still hold AnaptysBio stock options after the sale?

Yes. Footnote 5 states the insider holds additional options for 112,051 shares that vest according to their terms.

Was the AnaptysBio insider sale under a 10b5-1 plan?

Yes. The Form 4 confirms the sales were executed under a Rule 10b5-1 plan adopted on 03/14/2024.

What is the remaining direct share ownership of the AnaptysBio director?

After the transactions, the director directly owns 4,965 shares of ANAB common stock.